So­sei and Ver­i­ly part­ner on GPCRs; Ob­sE­va touts PhI­II da­ta in en­dometrio­sis pain

So­sei Hep­tares is team­ing up with a big-name part­ner: Al­pha­bet’s Ver­i­ly.

No fi­nan­cials were dis­closed, but the pair will aim to use Ver­i­ly’s im­mune pro­fil­ing and So­sei Hep­tares’ GPCR drug de­sign ca­pa­bil­i­ties to de­vel­op a va­ri­ety of new ther­a­peu­tics. The col­lab­o­ra­tion will fo­cus on GPCR drugs in the im­munol­o­gy, gas­troen­terol­o­gy and im­muno-on­col­o­gy spaces, as well as oth­er dis­or­ders with im­muno­pro­tec­tive or im­munopath­o­gen­ic mech­a­nisms, the com­pa­nies said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.